Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pharmaceutical Development Council Holds 1st Meeting; Aiming to Sort Out Priority Issues by March
October 29, 2020
- Bill to Amend Immunization Act Submitted to Diet
October 28, 2020
- MHLW Issues Notification on Establishing COVID-19 Vaccination Systems
October 28, 2020
- PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
- Reform Minister Asks MHLW to Facilitate Global Launch of Japan-Originated Medical Software Programs
October 27, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Continues to Collect Info on WHO-Led Study on Veklury
October 26, 2020
- MHLW Wants Distribution Improvement Confab by Year-End, Reckless Discounts Seen with Pricey Meds
October 22, 2020
- Xenograft Library Derived from Japanese Cancer Patients Now Up and Running
October 22, 2020
- No Skipping of Japanese Translation for COVID-19 Vaccine Dossiers: PMDA Official
October 21, 2020
- PMDA Sees Studies on Preventive Effect as a “Must” for Coronavirus Vaccines: Official
October 21, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Vice Health Minister Vows to Work on Law Amendment to Set Up Sound Vaccination Scheme
October 20, 2020
- Japan Cannot Boast of Its Development Status of COVID-19 Vaccines/Drugs: LDP Health Committee Chair
October 20, 2020
- 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30
October 19, 2020
- Japan’s Conditional Approval System for Regenerative Meds Is “Patient-Centered System”: PMDA Exec
October 19, 2020
- Japan Needs to Consider Legal Positioning of Stable Drug Supply Rules: Official
October 19, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
- Forxiga’s Heart Failure Use Up for PAFSC Discussion on October 29
October 16, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…